11.06.2021 MediClin AG  DE0006595101

DGAP-News: MediClin AG: Dr. Joachim Ramming becomes the new CEO of MEDICLIN


 

DGAP-News: MediClin AG / Key word(s): Personnel
MediClin AG: Dr. Joachim Ramming becomes the new CEO of MEDICLIN

11.06.2021 / 12:41
The issuer is solely responsible for the content of this announcement.


Dr. Joachim Ramming becomes the new CEO of MEDICLIN

In today's meeting, the Supervisory Board of MEDICLIN Aktiengesellschaft (MEDICLIN) has appointed Dr. Joachim Ramming as member of the Management Board of MEDICLIN and as Chairman of the Board. The PhD economist and health economist will succeed Volker Hippler on August 1, 2021, who is resigning his mandate as CEO and board member of the Company by mutual agreement with the Supervisory Board on June 30, 2021.

"We would like to thank Mr. Hippler for his commitment and the work he has done over the past five years and wish him all the best for his professional and private future. At the same time, we are pleased to have won with Dr. Joachim Ramming a leader with industry experience. Together with his colleagues of the Management Board, he will successfully drive the development of MEDICLIN further with strategic impulses", said Dr. Jan Liersch, Chairman of the MEDICLIN Supervisory Board.

For around 23 years, Dr. Joachim Ramming is active in the healthcare sector. He started his clinical career in 1998 immediately after studying economics as a trainee at RHÖN-KLINIKUM AG, where he learned how to manage a hospital from scratch. Around 20 years of management experience in clinic and hospital management followed, including eight years as managing director of hospitals at Sana Kliniken AG. From July 2015 until his appointment to the Management Board of MEDICLIN, Dr. Joachim Ramming works as managing director or regional managing director for the Asklepios Group, since March 2017 as regional managing director of Asklepios Kliniken Bayern. He is a member of the board of directors of the Association of Private Hospitals in Bavaria. V. (VPKA).

"I am very much looking forward to bring my experience to MEDICLIN and to start to sustainably develop the Company together with my two board colleagues, Tino Fritz and Dr. York Dhein,", said Dr. Joachim Ramming after his appointment and added: "Every crisis is also an opportunity. We must join forces to overcome the consequences of the corona pandemic for MEDICLIN and lead the company into the future. The entire team of the Management Board of MEDICLIN therefore sees the strategic and organizational development as the most urgent task for the coming months."

Dr. Joachim Ramming is a proven expert in the acute sector, he also knows the rehabilitation and medical care center business very well, and will also promote the consistent use of the synergies that arise from the cooperation within the Asklepios Group.

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)

MEDICLIN includes 35 clinics, seven care facilities and ten medical care centers. The Group has around 8,350 beds / care places and employs around 10,300 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a Company of the Asklepios Group.



11.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: [email protected]
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1207118

 
End of News DGAP News Service

1207118  11.06.2021 

fncls.ssp?fn=show_t_gif&application_id=1207118&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 609,08 645,11 673,09 659,86 673,14 704,70 730,07
EBITDA1,2 27,01 37,35 93,58 77,50 85,22 90,92 98,73
EBITDA-Marge3 4,43 5,79 13,90 11,74 12,66 12,90
EBIT1,4 6,62 15,06 22,41 0,15 11,56 19,52 12,72
EBIT-Marge5 1,09 2,33 3,33 0,02 1,72 2,77 1,74
Jahresüberschuss1 3,96 7,76 9,68 -0,04 1,49 9,72 -10,72
Netto-Marge6 0,65 1,20 1,44 -0,01 0,22 1,38 -1,47
Cashflow1,7 19,34 29,77 69,59 118,69 81,97 34,64 78,00
Ergebnis je Aktie8 0,08 0,16 0,20 -0,19 0,03 0,20 -0,23
Dividende8 0,05 0,05 0,05 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Mediclin
WKN Kurs in € Einschätzung Börsenwert in Mio. €
659510 2,600 Halten 123,50
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
10,00 19,19 0,52 19,55
KBV KCV KUV EV/EBITDA
0,63 1,58 0,17 1,45
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
0,00 0,00 0,00 06.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
02.05.2025 31.07.2024 04.11.2024 28.03.2025
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
7,08% 1,48% -5,11% -1,52%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MediClin AG  ISIN: DE0006595101 können Sie bei EQS abrufen


Pflegeeinrichtungen , 659510 , MED , XETR:MED